Summary: An in vitro model is presented for the study of glycosaminoglycans in human skin. The synthesis of six glycosaminoglycan species in both dermis and epidermis was measured by Z)-[ 3 H]glucosamine labelling. Punched biopsies (epidermis + entire dermis) of 3 mm in diameter were cultured at 37 °C in 5% carbon dioxide-95% air. When the label was added 18 h after explantation, the incorporation started immediately, and for all glycosaminoglycans the time-dependent incorporation was linear for 16h. The experimental variation was minimized by expressing the measurements in epidermis "per explant" and in dermis "per mg of wet explant". A ratio to dermal hydroxyproline did not improve the precision. Most of the variation arose "before" isolation and separation of the glycosaminoglycans. The labelled products were macromolecules and were converted to small molecules by chondroitinase ABC + heparinase. The total incorporation in dermis was 2 !/2 times higher than in epidermis. Hyaluronic acid was the predominant synthesized product in dermis, and hyaluronic acid and heparan sulphate were the predominant products in epidermis. The proportions (%) in dermis/epidennis were as follows: hyaluronic acid, 61/44; heparan sulphate, 18/31; dermatan sulphate, 5/8; chondroitin 4/6-sulphate, 10/7 and heparin-like glycosaminoglycan, 1/2. The same species were also demonstrated as native constituents of uncultured human skin. Hyaluronic acid and dermatan sulphate predominated in dermis, whereas no single species predominated in epidermis. Their concentrations in uronic acid equivalents per mg of wet skin (pmol/mg of epidermis + dermis) were as follows in dermis/epidermis: hyaluronic acid, 243/0.48; heparan sulphate, 22/0.44; dermatan sulphate, 170/0.56; chondroitin 4/6-sulphate, 72/0.50; and heparin-like glycosaminoglycan, 5/0.22. Thus, only 0.4% of the in vivo synthesized glycosaminoglycan was present in epidermis.
Introduction
tionships cell culture may not only result in distortion Glycosaminoglycans, mainly associated with proteins of cellular phenotype and karyotype (3) , but may also in proteoglycans, are important constituents of cell give misleading information about the glycosaminosurfaces and extracellular matrix (1) . As glycosami-glycan turnover. Thus, without physical contact benoglycans are believed to be involved in the control tween epidermis and dermis the epidermal synthesis of cellular differentiation and tissue development (2, of hyaluronic acid in cultured pig skin decreases con-3), in vitro studies of glycosaminoglycan in wound siderably (4) . Conversely, cultured corneal fibroblasts healing and cancer will probably attract more atten-also produce markedly less glycosaminoglycan in the tion in the future. For such studies cell culture is not absence than in the presence of corneal epithelium (6, always suitable. Without normal sociocellular rela-6,7).
Poulscn et al.: £>-[
3 H]Glucosamine labelling of glycosaminoglycans in cultured human skin Supported by the work of King and his associates (4, 8) we developed a reliable method for the study of glycosaminoglycan synthesis in cultured human skin by means of Z)-[ 3 H]glucosamine labelling. We believe that this method meets an acute need to study the synthesis of glycosaminoglycan in vitro, under conditions where "normal" mesenchyinal-epithelial relationships as well as cellular environments are preserved.
The characteristics distinguishing this method from others can be summarized as follows: the method needs only very small biopsies and is therefore suitable for studies on human skin; in fact all studies were performed on human skin. In the model the synthesis of 6 -7 glycosaminoglycan species is followed in both dermis and epidermis. Hence, not only major synthesis products like hyaluronic acid and heparan sulphate are measured, but reliable results are also obtained for minor products such as dermatan sulphate, heparin and chondroitin 4/6-sulphate. In addition we also measured the content of in vivo synthesized glycosaminoglycans in dermis and epidermis. By comparing these contents with the synthesis figures above, we were able to assess the relative rate at which each of these glycosaminoglycans is replaced in the tissues.
Acetic acid solution
50 mmol/1 acetate buffer, pH 5.5.
Carrier glycosaminoglycan
Post mortem skin, 5x5 mm 2 , treated with 1 mol/1 calcium chloride for l h at 37 °C, was deepithelialized, cut into pieces, washed 3 times in water and defatted in ether 4-acetone (3 -f 1 by vol.) at 37 °C for 1 h. The defatted dermis was disintegrated in a Thomas Wiley Micro Mill (Arthur H. Thomas Co., Philadelphia, USA), defatted for further 24 h in methanol + chloroform (3 + 1 by vol.) at ambient temperature and dried under vacuum. Fifty mg portions of dried dermis were digested at 67 °C for 7 h by 50 μΐ of "papain solution" (see below) in 1000 μΐ of "ethylene-diaminetetra-acetic acid solution" (see below). The resulting incubates were pooled and stored at -20 °C. The glycosaminoglycan concentration of the pool was measured in uronic acid equivalents on a cetyltrimethylamrnonium bromide precipitate (section VIII).
Cetyltrimethylammonium bromide solution
189 nmol/1 of Cetyltrimethylammonium bromide in 20 nmol/1 sodium chloride.
Culture medium
Minimum essential medium modified with Earle's salts, containing 20 nmol/1 of HEPES, 4 mmol/1 L-glutammej 44 mmol/1 of sodium bicarbonate, foetal calf serum, volume fraction 0.1, 10 4 units perl of penicillin and 100 mg/1 of streptomycin.
Materials and Methods

I. Materials
Keratan sulphate type I from bovine cornea, heparan sulphate from bovine kidney, and keratanase from Pseudomonas were obtained from Seikagaku Co., Japan. Hyaluronic acid grade III-S from human umbilical cord, hyaluronidase from 
III. Specimens of skin
All skin materials were of human origin and included epidermis and the entire dermis. The tissue culture experiments were performed on biopsies stored at 4 °C for less than 2 h in 5% carbon dioxide-95% oxygen-treated "culture-medium". Post mortem skin, stored at -20 °C, was used for measurement of native in vivo synthesized glycosaminoglycans and production of "carrier glycosaminoglycan".
IV. Tissue culture technique with jD-[
3 H]glucosamine labelling Punched skin disks with a diameter of 3 mm (== explant) were placed on siliconized lens papers, 15x15 mm 2 , with epidermis upward. Two grafts of explant-bearing lens papers were floated on 5 ml of "culture-medium" in a plastic petri dish with a diameter of 5 cm. The petri dishes were incubated in 5% carbon dioxide -95% air at 37 °C. After 18 h of incubation 1.85 MBq (50 μΟί) of />[ 3 H]glucosamine hydrochloride was added to each dish, and the culture was continued for further 16h. The incorporation was terminated by momentary freezing of the explants on dry-ice. The explants were kept at -20 °C until they were analysed.
V. Isolation of labelled glycosaminoglycan from dermis and epidermis
The explants were thawed, blotted on filter paper and weighed (= wet weight of the explant). After treatment in 1 mol/1 calcium chloride for l h at 37 °C epidermis was separated from dermis as an intact layer.
Dermis was washed for 10 min in 2 ml of water, cut into pieces, and dissolved in 400 μΐ of "ethylene-diaminetetra-acetic acid solution". Five μΐ of "papain-solution" was added and the sample was digested for 4 h at 67 °C, then sonicated for 15s, and digested overnight.
Epidermis was digested at 67 °C overnight by 5 μΐ of "papainsolution" in 250 μΐ of "ethylene-diaminetetra-acetic acid solution", sonicated for 10 s, and finally digested for further 4 h. The digested dermis and epidermis were then treated alike. After centrifugation for 5 min at 1900 g the supernatant was transferred to a plastic tube. "Carrier-glycosaminoglycan" with a uronic acid content of 45 nmol (about 200 μΐ) and 1800 μΐ of 20 mmol/1 sodium chloride were added. pH was adjusted to 11 and 300 μΐ of "cetyltrimethylammonium bromide" was added.
Then the first precipitation was initiated: after 2 h at ambient temperature the glycosaminoglycans were collected by centrifugation at 1900 g for 25 min. This centrifugation was repeated after a washing procedure with 600 μΐ of "acetic acid solution". The precipitate was redissolved by successive addition of 40 μΐ of Λ-propanol, 200 μΐ of «-propanol (volume fraction 0.6) in water-and 600 μΐ of ethanol. Fifty μΐ of 1.84 mol/1 sodium acetate was added, and the solution was left overnight in an ice-water bath. After centrifugation at 1900 g for 15 min the precipitate was redissolved in 50 μΐ of "tris buffer-deoxyribonuclease/ribonuclease-solution" and incubated for 5 h at 37 °C. One thousand μΐ of 20 mmol/1 sodium chloride and 200 μΐ of "cetyltrimethylammonium bromide-solution" were added to the digest. Then the second precipitation was started: apart from the washing procedure which was performed with water, the second precipitation was similar to the first one. The final precipitate was redissolved in 50 μΐ of "tris buffer-solution" and processed as described in the following section VI.
VI. Electrophoresis of labelled glycosaminoglycan
Electrophoresis was performed at pH 6.7 in 0.1 mol/1 phosphate buffer on strips of cellulose acetate (Schleicher and Sch ll, FRG), 25 χ 180 mm 2 . Twenty μΐ of the glycosaminoglycan preparation from the preceding section V was applied as a strip, 2 cm from the margin of the cathode wick, and processed for 60 min at 10 V/cm. The remaining 30 μΐ of the glycosaminoglycan-solution was incubated for 60 min at 37 °C with 0.20 U of chondroitinase AC. After addition of 7.5 nmol uronic acid equivalents of heparan sulphate an electrophoresis of 20 μΐ of the digested glycosaminoglycan-solution was performed. The strips were stained for 5 nun in "Alcian Blue-solution", 40 ml per strip, dipped in 50 ml/1 acetic acid, and washed twice for 3 min in 50 ml/1 acetic acid, 40 ml per strip. The labelled glycosaminoglycans were recovered in three electrophoretic bands (b, c and d in fig. 1 ) detected on the cellulose acetate by the Alcian Blue-stained carrier glycosaminoglycans. Guided by these 3 bands 6 fractions (a, b, c, d, e, and f in fig. 1 ) were cut out from each cellulose acetate electrophoresis, transferred to counting tubes and dissolved overnight in 3 ml of concentrated acetic acid. The labelled fractions were then counted as described in the following section VIL VII. Liquid scintillation counting of labelled glycosaminoglycan-species After addition of 16 ml of Pico-Fluor to the acetic acid solution of dissolved cellulose acetate and labelled glycosaminoglycan the tube was counted in a Tri-Carb 2450 liquid scintillation counter (Packard, USA) for 4 min or up to 10000 counts. All the radioactivity was located in fractions b, c and d. No significant activity was ever measured in fractions a, e and f. The counts of the f-fractions were used as blank values and were subtracted from the counts of the remaining fractions. The radioactivity of the individual glycosaminoglycan-species were calculated as shown in table 1 using the "B-formulas". Originating from samples of 20 μΐ, this radioactivity represented 2/5 of the activity in the whole explant. To present the actual count figures we expressed the epidermal results as counts/min · 20 μΐ (reduced to counts/min in tables and figures) and the dermal results as counts/min · 20 μΐ · mg wet explant (reduced to counts/ min · mg in tables and figures).
Tab. 1. Calculation of radioactivity or densitometric scanning area of glycosaminoglycan species separated by electrophoresis and enzyme pretreatment. Depending on the separation procedure used, calculations were performed by two sets of formulae, A and B. The origin of the raw data used in the formulae can be deduced from the "Roman numeral-letter" combinations. The Roman numeral indicates whether the sample was electrophoresed without (I) or after treatment with chondroitinase AC (II) or chondroitinase ABC (III). The letter indicates whether the measurement (radioactivity or scanning area) originates from the electrophoretic fractions b, c, or d (see fig. 1 ).
Glycosaminoglycans
Hyaluronic Fifty and 57 mg of dried defatted dermis and epidermis were prepared and digested by papain (sections II and V). Using a scaled-up version of the method described in section V, without adding "carrier-glycosaminoglycan", the native glycosamin<> glycans were isolated in a "tris buffer solution". By measuring the uronic acid content of this solution (section X) the total tissue concentration of glycosaminoglycans was calculated. On the remaining material the percentages of the glyc saminoglycan-species were established as described below. The product between the total concentration and these percentages gave the uronic acid concentration of the individual glycosaminoglycanspecies. The glycosaminoglycans were fractionated by electro?· phoresis as described in section VI. An amount of glycosaminoglycan equivalent to 5 nmol of uronic acid was electrophoresed without and after treatment for 60 min at 37 °C with 0.013 U of chondroitinase AC, 0.013 U of chondroitinase AC + 0.008 U of chondroitinase ABC, or 0.013 U f chondroitinase AC + 0.008 U chondroitinase ABC + 3.6 μg of heparinase, respectively, per nmol of uronic acid. The wet strips were stained with Alcian Blue and scanned at 620 nm (0.1 mm slit) in a Cliniscan (Helena Laboratories, USA). The densitometric scanning areas of the individual glycosaminoglycan-species were calculated as described in table 1 using the "A-formulas". Preliminary studies .showed that these areas correlated linearily with the amount of 'glycosaminoglycan (< 5 nmol of uronic acid equivalents); but unfortunately the glycosaminqglycanspecies took up stain with different affinities. The scan-areas were therefore corrected for differences in stainability before they were used for calculating the skin concentrations of the individual species. The uptake of Alcian Blue per mol uronic acid by heparin, hyaluronic acid, heparan sulphate, chondroitin 4-sulphate, and dermatan sulphate were related to each other as 1.8 to 0.7 to 1.0 to 1.0 to 1.0. The concentrations of epidermal and dermal glycosaminoglycan-species were expressed in uronic acid equivalents as pmol/mg of wet explant.
IX. Characterization of chondroitinase AC susceptible material in band c
Glycosaminoglycans from 50 mg of dry dermis were isolated, incubated with 1 Unit of Streptomyces hyaluronidase in 60 μΐ of "hyaluronidase buffer" for 2 h at 60 °C. The incubate was reprecipitated, electrophoresed with and without previous chondroitinase treatment, stained with Alcian Blue and scanned.
X. Measurement of uronic acid, hexosamine and hydroxyproline Methods described elsewhere were used for colorimetric measurement of uronic acid (10) and hexosamine (10) . The content of hydroxyproline in dermis was measured by the Hypronosticon® test from Organon (Holland). Fifty μΐ of papain-digested dermis mixed with 450 μΐ of water was analysed as described in the manufacturer's instructions.
Results
Substrate specificity of keratanase, heparinase, chondroitinase AC, and chondroitinase ABC
The enzymes used were initially tested against authentic preparations of glycosaminoglycans. The enzymes in question were incubated for 60 min at 37 °C with hyaluronic acid, chondroitin 4-sulphate, dermatan sulphate, hepariii, heparan sulphate and kefatan sulphate type I; they were all present at uronic acid or hexosamine concentrations of 30 nmol in 60 μΐ "tris buffer solution". Digested and undigested substrates were processed by cellulose acetate electrophoresis, and the effect of the enzymes was measured by the reduction they produced in the klcian Blue poŝ itive material on the electrophoresis strip.
Chondroitinase AC (0.3 unit) only digested hyaluronic acid and chondroitin 4-sulphate. Digestion by chondroitinase AC did not change the mobility or stainability of dermatan sulphate from porcine skin, when electrophoresed on cellulose acetate. Chondroitinase ABC (0.1 unit) in addition digested dermatan sulphate. When the authentic glycosaminoglycans were incubated with 10 μg of heparinase (in fact a crude preparation of heparinase and heparitiriases), all except keratan sulphate and dermatan sulphate were completely digested. Dermatan sulphate was not totally digested until the amount of heparinase was increased to 48 μg. Keratan sulphate resisted incub ation with 90 μg of heparinase. Keratanase (0.12 and 0.24 unit) was only active against keratan sulr phate, but unveiled 21 % of resistant material with an 18% higher electrophoretic mobility than the original keratan sulphate fraction. This material may represent polysulphated keratan sulphate, which resists degradation by keratanase according to the manufacturer, and Muir & Hardingham (1).
Labelled glycosaminoglycans in epidermis and dermis
Glycosaminoglycan from dermis or epidermis, gives the same 3 electrophoretic fractions b, c and d ( fig.  1 ). Dermal glycosaminoglycans could therefore be used as electrophoretic markers of labelled glycosaminoglycans from both epidermis and dermis. The labelled fractions were cut out from the cellulose acetate strips, solubilized in acetic acid and mixed with scintillation liquid (sections VI and VII). The solutions were homogeneous and clear, but contained solubilized cellulose acetate and Alcian Blue. As shown in figure 2 the counting efficiency did tiot change with increasing concentrations of both these components.
It was shown that the labelled, in vitro synthesized glycosaminglycans also separated into three distinct bands, with low activities (less than 26% of the total) in the electrophoretic areas between the b, c and dbands (activity/cm carrier-glycosaminoglycan. Carrier-glycosaminoglycan of dermal origin, used for the isolation of labelled glycosaminoglycans, was separated into three bands, b, c and d, as described in section VI. These bands as well as a narrow strip anodic to band b (= fraction a) and two strips cathodic to band d (= fraction e and f) were cut out for radioactivity measurements. All six fractions had equal dimensions and constituted an adjoining piece of the cellulose acetate strip. Fraction f was used for establishing a blank value.
and f. Fraction f, used for establishing a blank value, thus contained less than t % of the radioactivity in each of the b-, c-, and d-bands.
Removal of labelled material from the electrophoretic fractions by previous treatment with the enzyme combinations presented in minoglycan from dermis and epidermis were prepared from skin cultures processed as described in methods sections IV and V, but with twice as much labelled glycosaminoglycans in the electrophoresis sample as usual (labelled glycosaminoglycan/carrier glycosaminoglycan = twice the usual ratio). Each pool was redistributed in 5 volumes of 70 μΐ which were incubated at 37 °C for 8 h without and with the enzyme combinations presented in the Other experiments showed that band c contained minor amounts of chondroitinase AC-susceptible material not digested by hyaluronidase from Streptomyces (section IX). "Compound X'* (Ic-IIIc/Ic-IIc in tab. 1) might therefore be low sulphated chondroitin sulphate, but the final identity of "compound X" remains to be proved. The radioactivity of the individual glycosaminoglycan-species was calculated on the basis of the raw data in table 2. These radioactivity values are presented in the left part of table 3. Hyaluronic acid was the predominant product of synthesis in both dermis and epidermis, constituting 61% and 44% respectively. In epidermis the synthesis of heparan sulphate was almost of the same magnitude (31%). The remaining glycosaminoglycan-species were synthesized at lower rates, each constituting from 1% (dermal heparin) to 18% (dermal heparan sulphate) of the synthesized products. On the whole the synthesis in dermis was 2V4 times higher than in epidermis.
Unless it is important to differentiate between the synthesis of dermatan sulphate and the much smaller synthesis of heparin, a less time-consuming method is recommended which only makes use of one of the enzymes: the treatment with chondroitinase AC. This method measures the synthesis of hyaluronic acid, heparan sulphate, "dermatan sulphate" (contamin ated with a small fraction of heparin), chondroitin 4/6-sulphate, chondroitinase AC-susceptible material in band c (compound X) and resistant material in d (compound Y). The following experiments were all performed with this simplified method (the method described in detail in the experimental section).
For all glycosaminoglycans concerned, apart from "compound Y", a linear time-dependent incorporation of jD-[ 3 H]glucosamine was found in both epidermis and dermis during the first 16 hours of labelling ( figs. 3 and 4) . The incorporation started immediately after addition of the radioactivity. During the first 16 hours the labelling rate of the different glycosaminoglycan species could therefore be compared under equal conditions, i. e. where the rate of synthesis is higher than the rate of degradation. As shown for only hyaluronic acid and heparan sulphate ( fig. 5) , the proportions of all glycosaminoglycan species remained constant throughout the entire labelling time.
Tab. 3. Synthesis of glycosaminoglycans in skin culture and concentration of in vivo synthesized glycosaminoglycans of uncultured skin. The mean synthesis of glycosaminoglycans in epidermis and dermis was calculated on the basis of the raw data in table 2 using the "Α-formulae" of table 1. In addition, glycosaminoglycan from epidermis and dermis of uncultured skin was isolated and separated into species by enzyme treatment and electrophoresis in the same way as labelled glycosaminoglycan. The densitometric scanning areas of the Alcian Blue-stained species were calculated using the "A-formulae". On the basis of a uronic acid measurement of total glycosaminoglycans in epidermis and dermis, the uronic acid concentration in wet skin of each of the epidermal and dermal species was assessed (pmol/mg wet skin). For details see section VIII. Fig . 3 . Time-dependent labelling of glycosaminoglycans in epidermis of cultured skin. Procedures were as described in section IV-VI. Explants, punched from the skin in 4 persons, were cultured with 2 explants in each dish, and labelled for 4, 7,10,13, and 16 h. The radioactivity of the glycosaminoglycan species was measured. Double determinations, made on explants from the same dish, are shown together with the regression line describing the time-labelling relationship (calculated by least squares fit).
The experimental variation was minimized by expressing the epidermal synthesis per explant rather than per mg wet explant, and the dermal synthesis per mg wet explant rather than per explant (results not shown). The synthesis of glycosaminoglycan-species in 12 explants, punched out of the same piece of skin, was measured (tab. 4). The resulting standard deviations, calculated on a basis of 6 double measurements, demonstrated the overall variation arising from the culture process and from the isolation and separation of the labelled glycosaminogjycans. The greatest variation was found in the epidermal results and, independent of tissue origin, in "compounds X and Y". No convincing improvement of tue precision was gained by expressing the results per μτηοΐ of dermal hydroxyproline (tab. 4).
Experiments designed to trace the source of experimental Variation were also performed (tab. 5). Half of the glycosaminoglycan-extracts from 12 cultured explants were pooled and redistributed into 6 samples. These samples as well as the 6 unpooled samples were analysed?, and the coefficients of variation (CV) from the pooled and unpooled samples were compared. The reduction in CV produced by pooling the extracts showed that most of the variation in the epidermal measurements arose in the culture process or was due to variation in synthesis within the piece of skin from which the explants had been punched out. The same was true for dermal hyaluronic acid and heparan sulphate. Most of the variation in the measurements of dermal dermatan sulphate, Chondroitin 4/6 sulphate and "compound X", on the other hand, arose in the isolation and separation procedures. It is uncertain why the CV of pooled epidermal samples were lower than the CV of pooled dermal samples.
The H]Glucosarnine labelling of glycosaminoglycans in cultured human skin Tab. 4. Assessment of the experimental variation in the skin culture. Procedure were exactly as described in sections IV-VII. Twelve explants, punched out from the same piece of skin, were cultured with 2 explants in each dish. Labelled glycosaminoglycans were papain-extracted, precipitated by cetyltrimethylammonium bromide and separated toy electrophoresis and enzyme pretreatment. The radioactivity of each glycosaminoglycan was calculated using the "B-formulae" synthesized glycosaminoglycans from both sources were isolated in the presence of surplus carrier glycosaminoglycan of dermal origin. It may be that the epidermal glycosaminoglycans are in a state that enhances their quantitative precipitation.
Sepharose 6B column chromatography demonstrated that the dermal and epidermal material, synthesized in vitro was polymeric, and that it could be degraded by chondroitinase ABC + heparinase into oligomeric material eluting at the V t ( fig. 6 ). However a small fraction (2%) of the glycosaminoglycans synthesized in epidermis still eluted in the void volume after digestion. The significance of this is discussed below. Glycosaminoglycans isolated from dermis which had not been cultured behaved in the same way as the radioactive material in the Chromatographie procedures.
For the results presented a complete separation between epidermis and dermis was of course essential. Cross-sections of an entire explant showed that this was actually achieved by the calcium chloride treatment.
In vivo synthesized glycosaminoglycans.from uncultured epidermis and dermis 
itinase ABC and heparinase: Fraction b consisted of chondroitin 4/6 sulphate, dermatan sulphate and heparin-like glycosaminoglycans. Fractions c contained mainly heparan sulphate, susceptible to heparinase, but also' material susceptible to chondroitinase AC or ABC (compound X). Both hyaluronic acid and keratan sulphate migrated with fraction d. However it was completely removed by chondroitinase AC and fraction d was hence identified as hyaluronic acid.
Successive removal of glycosaminoglycan species from the electrophoretic fractions by enzymes made it possible to determine the uronic acid concentration in whole skin of 6 epidermal and 6 dermal glycosaminoglycans. The results were compared with the synthesis figures in table 3. More than 99% of the skin glycosaminoglycans were found in dermis. The predominant constituents of dermis were hyaluronic acid and dermatan sulphate, constituting 47% and 33% respectively, whereas dermal chondroitin 4/6 sulphate, heparan sulphate and heparin constituted only 14%, 4% and 1%. In epidermis the proportions of heparan sulphate and heparin were much higher, con-' ' ' ' ' stituting 20% and 10% respectively. Epidermal hyaluronic acid, dermatan sulphate and chondroitin 4/6-_ .
sutohate constituted 22%, 25% and 23% . It is evident 
hat these tissue concentrations do not reflect the rates by which the glycosaminoglycans are synthesized in the explants. The significance of this is discussed below.
Discussion
The labelled products in the skin explants were identified as glycosaminoglycan on the basis of different characteristics: the products resisted digestion by papain, deoxyribonuclease and ribonuclease. They com-2O 30 40 50 plexed with cetyltrimethylammonium bromide at V t Fract'on no t V* P^ 5 anc * were e^ute^ fr°m a Sephrose 6B column as Fig. 6 . Sepharose 6B chromatography of glycosaminoglycans from uncultured skin and labelled glycosaminoglycans from cultured skin explants before (--) and after ( ) enzymatic digestion. Preparations of labelled glycosaminoglycan were isolated from 16 explants as described in sections IV and V. From these preparations a dermal and an epidermal pool were made. Each pool was divided into two halves which were incubated without and in the presence of chondroitinase ABC + heparinase at 37 °C for 8 h respectively. The solutions were applied to a 0.5 χ 150 cm Sepharose 6B column, and the labelled material was eluted by 0.1 mol/i phosphate buffer, pH 5.0, at a flow rate of 2.4 ml/h. Fractions of 0.5 ml were collected and every second fraction was counted in the presence of 5 ml of Pico-Fluor. In vivo synthesized glycosaminoglycan, isolated from dermis of post mortem skin as described in section VIII, was chromatographed in the same way, and monitored as uronic acid.
cans. In cellulose acetate electrophoresis the labelled products migrated with authentic glycosaminoglycans and native glycosaminoglycan from dermis and epidermis. After treatment with chondroitinase ABC plus heparinase, the labelled materials were eluted from the Sepharose column as small molecules and became undetectable by cellulose acetate electrophoresis. However, some 2% of the labelled material still appeared in the void volume when labelled epidermal glycosaminoglycans were eluted after digestion ( fig.  6 ). We do not believe that this residue is the result of an insufficient proportion of enzyme in the digest, or the presence of any inhibitors. When glycosaminoglycan preparations of all kinds other than keratan H]Glucosamine labelling of glycosaminoglycans in cultured human skin sulphate were added to the incubate they were completely degraded under the conditions used. The undigested material from epidermis may be either keratan sulphate or contaminating cell surface associated glycoconjugates which are known to also incorporate [ 3 H]glucosamine (4, 8) . Glycoconjugates of low charge density may very well appear in the void volume and be absent from the electrophoretic zones of glycosaminoglycans. This was in fact what was seen in our results.
Dermatan sulphate, including dermatan sulphate from pig skin as an example, is a copolymer with chondroitinase AC-susceptible disaccharide units of chondroitin 4-sulphate (11) . Digestion by chondroitinase AC however did not change the mobility or stainability of dermatan sulphate from porcine skin when electrophoresed on cellulose acetate. The dermatan sulphate oligosaccharides produced in this way maintain mobility and stainability of the parent dermatan sulphate. Hence there is no reason to believe that the low labeling rate of dermatan sulphate was due to loss of dermatan sulphate oligosaccharides.
The present model uses skin biopsies which includes epidermis and the entire dermis and measures the synthesis of glycosaminoglycans in both layers. As papain treatment extracts both cellular and extracellular glycosaminoglycans from the tissue (8) the model does not distinguish between these sources.
Labelled glycosaminoglycans may be lost in the calcium chloride solution used to separate epidermis from dermis. This was the case when the separation was performed by trypsin or dispase treatment (4), but according to King & Tabiowo (4) the adopted separation procedure, using calcium chloride incubation, was superior to the enzyme methods with respect to this source of error.
As in all culture experiments the same batch of foetal calf serum should be used for comparative studies, and whenever possible one should culture two explants from each individual, as most of the experimental variation arose "before" isolation and separation of the labelled glycosaminoglycan. By expressing the radioactivity per μιηοΐ of dermal hydroxyproline no improvement in precision was gained. The experimental variation was minimized by expressing the epidermal counts "per explant" and the dermal counts "per mg of explant".
A labelling time of 16 hours ensured that the incorporation-time relationship had not reached a plateau for any of the glycosaminoglycan species. The labell? ing rate of the species could therefore be compared under equal conditions. The labelling rate of glycosaminoglycan was 2!/ ? times higher in dermis than in epidermis. This difference could hardly be explained by differences in the number of cells between the two layers, although the dermal number exceeded that of the epidermis by 15% to 70% (range of cell counts in four cross sections). Hyaluronic acid, heparan sulphate, dermatan suU phate, chondroitin 4/6-sulphate, hepario, and a chondroitinase AC-susceptible fraction with the mobility of heparan sulphate (compound X) were demonstrated as in vivo constituents in both dermis and epidermis. The same species were also synthesized there in vitro. However, there was no proportionality between the tissue concentrations and the in vitro synthesis rates. In dermis the concentration of dermatan sulphate equalled the concentration of hyaluronic acid, and considerably exceeded the concentration of heparan sulphate. Nevertheless the dermal synthesis of dermatan sulphate was much smaller than the dermal synthesis of both hyaluronic acid and heparan sulphate. Likewise the synthesis of hyaluronic acid and heparan sulphate were very predominant in the epidermal synthesis, but no single glycosaminoglycan species predominated in the in vivo synthesized glycosaminoglycan pool of uncultured epidermis.
Tab. 6. The relative turnover rate of glycosaminoglycan species assessed by in vitro and in vivo investigations. The turnover fate of dermatan sulphate is used as a unit of measurement. For further explanation see "Discussion".
In A broad range of investigations on the structure and mechanism of flavoenzymes, structure and electron transfer mechanisms, and biosynthesis and medical aspects are presented. This book contains the most recent compilation of research efforts and views on the biological function of vitamin B 2 (flavins). Approaches used in the contributions range from x-ray crystallography and NMR spectroscopy to gene cloning techniques. 
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On the basis of the results in table 3 we therefore calculated the ratio between the labelling rate and the tissue concentration of glycosaminoglycan for each species (tab. 6). If the in vitro synthesis reflects the pattern of synthesis in vivo, this ratio is directly proportional to the rate by which the pool of a certain glycosaminoglycan species is replaced at steady state. This turnover was much higher in epidermis than in dermis, probably because the greater part of the glycosaminoglycans in dermis, unlike the glycosaminoglycans in the cell-rich epidermis, is so far from the cells that they only participate in the turnover to a limited extent (in the intact skin).
To our knowledge it has not been shown before that heparin-like glycosaminoglycan is present in a relative large amount in epidermis, and that heparin is synthesized there. In this report heparin or heparin-like glycosaminoglycan however was defined somewhat arbitrarily as heparinase-susceptible and chondroitinase ABC-resistant glycosaminoglycan migrating with heparin. No attempts were made to characterize this fraction by its protein core structure or by its anticoagulant activity (12) . Hence it may be that this heparin fraction only represents some highly sulphated heparan sulphate.
Endothelial cells also produce heparin-like substances which in vitro have been shown to stimulate the synthesis of glycosaminoglycan by arterial smooth muscle cells while markedly decreasing the proliferation of these cells (13 -14) . It is possible that the heparin-like substances in epidermis have a similar effect in the epithelial-mesenchymal relationship of skin.
In table 6 we have also presented results from an earlier in vivo investigation (16) . On the basis of a direct proportionality between the urine excretion and the dermal concentration of heparan sulphate and dermatan sulphate, it was tempting to calculate the ratios between corresponding urine and tissue measurements as an attempt to estimate the relative turnover of the two glycosaminoglycans in the dermis. The metabolic fate of heparan sulphate and dermatan sulphate is hardly the same, and the urine-tissue ratios are probably inaccurate or may be even misleading measures of the in vivo turnover. Hence it may be pure chance that these figures show the same pattern as the ratios between the in vitro synthesis and the tissue concentration of heparan sulphate and dermatan sulphate (tab. 6).
